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SUMMARY: Cholinergic system in CNS is involved in learning and memory. Scopolamine as muscarinic acetylcholine recep-
tor antagonist is used for creation of memory impairment. The purpose of this study is evaluation of scopolamine-based amnesia on
memory retention and the effect of this phenomenon on the number of neurons contains M1-receptors in the male Wistar rats hippocampal
regions. Thirty-five male Wistar rats (200±20 g) were distributed randomly into five groups. Control group (intact samples) and 3
experimental groups with sham group (saline) were tested by the method of passive avoidance (shuttle box) in doses of 0.2, 0.5 and 1
mg/kg (intraperitoneally) as a single dose. After one week, memory test was taken from the rats. Finally, brains dissected from sacrificed
rats, and then processed tissues were stained with antibody against M1 receptors (Immunohistochemistry technique) followed by counting
of hippocampal CA1, CA3 and DG regions. Our results showed significant decrease in neurons contains M1-receptors in all area of
hippocampus. We found that the less number of M1-neurons showed in 1 mg/kg dose of scopolamine. We concluded that scopolamine
as muscarinic acetylcholine receptor antagonist can reduce dose-dependently the density of M1-neurons in all areas of hippocampus.
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INTRODUCTION
The hippocampus as the main part of limbic system
is a key structure in the formation and retention of memory.
Acetylcholine is one of several neuromodulators in the
hippocampus and most of its known effects are mediated by
the muscarinic family of receptors (M1±M5). Cholinergic
basal forebrain neurons in Alzheimer's disease Degenerated
and it has been suggested to contribute to the dementia
syndrome (Rouse et al., 2000).
We have two types of acetylcholine receptors,
muscarinic and nicotinic (Chiba et al., 2010), and  muscarinic
acetylcholine receptors divided to five subtypes: M1, M2,
M3, M4, M5 (Volpicelli & Levey, 2004; Lebois et al., 2009).
Although the role of each subtype is poorly known, in the
hippocampus the muscarinic receptors are related to learning
and memory (Ferreira et al., 2003).
In central and peripheral nervous system the
muscarinic acetylcholine receptors (mAChRs) play critical
functions in regulating the activity of many important functions
(Bymaster et al., 2003). The hippocampus and prefrontal cortex
that important for cognition are expressed the highest levels
of M1 and M2 receptors (Haley et al., 2011). In these regions
amyloid plaques developed in Alzheimer's disease brains and
this receptor subtype has long been assumed as a potential
therapeutic target (Langmead et al., 2008).
Scopolamine known as hyoscine, a nonspecific
muscarinic receptor antagonist, confers impairment of learning
acquisition and short-term memory and reduces neuronal
density in the rats' hippocampus (Seifhosseini et al., 2011).
Some evidence indicate the between Alzheimer’s disease
patients and scopolamine treated animals is exist similarities
in the memory deficit (Azami et al., 2010).
Therefore, the main question was whether scopolamine
(muscarinic antagonist) is effective only on the function of
receptors or it is effective on the number of neurons containing
receptors. On the other hands, the aim of this study was to
evaluate the effects of scopolamine (as muscarinic receptor
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antagonist) on the density of neurons contain M1 receptor
in male Wistar rats hippocampal formation.
MATERIAL AND METHOD
Animals. Thirty-five male Wistar rats (Pasteur Institute,
Amol, Iran), weighting 200±20 g at the time of training,
were used in passive avoidance task. They had free access
to food and water, were housed seven in a cage, and kept at
controlled temperature (22±2°C) under a 12/12 h light-dark
cycle (light beginning at 07:00 h) at least 1 week before the
beginning of the experiments.
The rats were randomly distributed into five groups
(n = 7) as follows:
1. Control: Without receiving scopolamine and behavioral
test.
2. Saline-control: received saline + behavioral test.
3. Exp. 0.2 mg/kg: received scopolamine (0.2 mg/kg IP) +
behavioral test.
4. Exp. 0.5 mg/kg: received scopolamine (0.5 mg/kg IP) +
behavioral test.
5. Exp. 1 mg/kg: received scopolamine (1 mg/kg IP) +
behavioral test.
All experiments were carried out during the light
phase between 09:00 and 15:00 h. Experimental groups
consisted of 7 animals and each animal was tasted once only.
All procedures were performed in accordance with
institutional guidelines for animal care and use.
Drugs. Scopolamine hydrobromide (Tocris, Bristol, UK)
was dissolved in saline (NaCl 0.9%) at final concentrations
of 0.2, 0.5 and 1 mg/kg, and was injected intraperitoneally
one day after the training.
Inhibitory Avoidance Procedures. Our previous studies
(Azami et al.; Seifhosseini et al.) described passive
avoidance as follows: each animal was gently placed in the
brightly lit compartment of the apparatus; after 5 s the
guillotine door was opened and the animal was allowed to
enter the dark module. The latency with which the animal
entered the dark chamber was recorded. Animals that waited
more than 120 s to enter the dark chamber were excluded
from the experiments. Once the animal entered with all four-
paws to the next chamber, the guillotine door was closed
and the rat was immediately withdrawn from the
compartment. This trial was repeated after 30 min. As in the
acquisition trial, after 5 s the guillotine door was opened,
and as soon as the animal entered the dark (shock)
compartment the door was closed; and a foot shock (50 Hz,
1 mA and 3 s) was immediately delivered to the grid floor
of the dark room. After 20 s, the rat was removed from the
apparatus and placed temporarily into its home cage.
The animal was retested two minutes later, in the same
way as in the previous trials; if the rat did not enter the dark
compartment during 120 s, a successful acquisition of
inhibitory avoidance response was recorded. Otherwise,
when the rat entered the dark compartment (before 120 s) a
second time, the door was closed and the animal received
the shock again. After retesting, if the rat learned inhibitory
avoidance response successfully, it was moved to the cage
and 24 h after the training, received scopolamine or saline
(i.p.). On the test day (one week after training) each animal
gently placed in the light compartment and after 5 s the door
was opened, and step through latency (sec) was recorded in
the absence of electric foot shocks, as indicator of inhibitory
avoidance behavior.
Histology. Animals were deeply anesthetized with
chloroform, decapitated and the brains removed from the
skull and remained in paraformaldehyde (4%) for two weeks,
and then, the brains transfer to tissue processor apparatus.
Following this session, samples of the brain were embedded
in paraffin and kept in refrigerator. Then the brains were
sliced at a thickness of 8 mm in the coronal plane (from
Bregma –2.5 mm to –4.5 mm of the hippocampal formation)
(Paxinos & Watson, 1998) with a rotary microtome (MK
1110).
Immunohistochemistry. At first samples incubated (30 min)
at 37°C, then, for deparaffinization and hydrate procedures
embedded in xylene and different degrees of ethanol. After
these the samples washed in purified water. Following this
stage the sections were embedded in epitope retrieval for 20
min, at 90°C (IHC World, USA). After this the samples
remained in room temperature for 20 min.
For buffered washing the samples were washed two
times in PBS/Tween 20 (IHC World, USA).  Following block
step carried out with proxidase blocking solution (3% H2O2
in PBS) (10 min, at room temperature). After the blocking,
sections were washed two times in PBS/Tween20. The
sections were blocked with Avidin/Biotin Blocking Solution
(IHC World, USA) (for 30 min at room temperature),
polyclonal primary antibody (M9808, Sigma-Aldrich) was
applied at 1:200 dilution and the sections were incubated
for 1 h at 37°C. after this stage the sections washed one time
in PBS/Tween20 (10 min), then incubated in biotinylated
goat anti rabbit IgG (abcam) for 1 h at 37°C, then,
Streptavidin protein (HRP, abcam) diluted 1:5000 (30 min,
room temperature), and washed in PBS/Tween 20 (10 min),
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and visualized with DAB. Finally, the sections were
dehydrated in ethanol, cleared in xylene and cover slipped
with entellan (Fig. 1).
a significant difference between sham and experimental
groups (p<0.05). We found no significant difference between
the experimental groups with the other.
Stained slides were visualized using a system
composed of a binocular microscope, Equipped with a digital
video camera connected to a video monitor. Using OLYSIA
Autobioreport software, Olympus Co, the appropriate grids
were superimposed on the pictures and the cells were counted
manually in 30000 mm2. To perform an unbiased
measurement, the individual was double-blinded and only
the cells with significant M1 cell characteristics were counted
(Jahanshahi et al., 2006; Jahanshahi et al., 2011).
Statistical Analysis. Comparisons between groups were
made with one-way analysis of variance (ANOVA). Post-
hoc comparison of means was carried out with the Tukey
test for multiple comparisons, when appropriate. A difference
with p≤0.05 between the experimental groups was
considered statistically significant.
RESULTS
The latency of response in the sham group was
128.57±97.48 s, while for the experimental groups it was a
much shorter time (0.2 mg/kg = 52.86±9.51 s, 0.5 mg/kg =
50.86±57.32 s and 1mg/kg = 26.57±34.07.48 s). Data showed
Fig. 1. Micrograph of CA3 area of hippocampus with Anti-
M1 immunohistochemistry staining. Neurons contain M1
receptor in their membrane showed brown.
P value Std. Deviation Mean Groups – CA1
8.021 38.25 Control
0.769 15.412 41.94 Sham-Saline
0.001 6.557 25.06 Scopolamine 0.2
0.000 6.329 22.06 Scopolamine 0.5
0.000 3.623 14.06 Scopolamine 1
P value Std. Deviation Mean Groups – CA3
7.641 34.88 Control
0.855 9.562 37.31 Sham-Saline
0.000 7.125 20.31 Scopolamine 0.2
0.000 4.542 14.69 Scopolamine 0.5
0.000 4.082 13.44 Scopolamine 1
As we showed in Table I, scopolamine decreased the
number of M1 cells in CA1 area of hippocampus (p<0.001).
This decrease was dose-dependent. The less number of
neurons contains M1 receptors showed in 1 mg/kg dose of
scopolamine (14.06 ± 3.62). There is no difference
statistically between control and sham groups.
In Table II we showed the Mean and SD of neurons
contains M1 number in CA3 area of hippocampus. The less
number of neurons contains M1 receptors showed in 1 mg/
kg dose of scopolamine (13.44 ± 4.08). The differences were
significant statistically in all doses (p<0.001).
P value Std. Deviation Mean Groups – DG
11.387 49.94 Control
0.986 21.312 52.25 Sham-Saline
0.000 11.964 21.94 Scopolamine 0.2
0.000 7.971 19.75 Scopolamine 0.5
0.000 4.199 13.81 Scopolamine 1
Table I. Mean and SD of muscarinic (M1) cells number in CA1
area of Hippocampus.
Table III. Mean and SD of muscarinic (M1) cells number in DG
area of Hippocampus.
Table II. Mean and SD of muscarinic (M1) cells number in CA3
area of Hippocampus.
In dentate gyrus (Table III), the less number of
neurons contains M1 receptors showed in 1 mg/kg dose of
scopolamine (13.81 ± 4.19).
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DISCUSSION
This study was conducted to evaluate that effect of
scopolamine-based amnesia on the density of M1-
muscarinic neurons with immunohistochemistry technique.
We found that scopolamine in all areas of hippocampus
reduced the number of neurons contain the M1 receptor
dose dependently. Unfortunately we could not recognize
only the number of M1 receptors with this method.
The most highly expressed muscarinic receptor in
the prefrontal cortex and hippocampus is the type 1 (M1)
(Fredrickson et al., 2008; Nathanson, 2008). Some previous
studies indicate the role of muscarinic receptors to
avoidance memory, for example, Power and co-workers
demonstrated that both M1 and M2 pharmacological re-
ceptor subtypes were important for memory consolidation
of inhibitory avoidance (Power et al., 2003). As we show,
Injection of scopolamine as a muscarinic antagonist intra-
hippocampal (Azami et al.) or intra-peritoneal (Kwon et
al., 2009; Seifhosseini et al.) impairs the avoidance
memory. The other antagonist, pirenzepine, injected
bilaterally into the dorsal hippocampus, significantly
increased the number of errors in working memory (Ohno
et al., 1994).
Other reports indicate an age-related decrease in M1
receptor (Wagster et al., 1990; Vannucchi & Goldman-
Rakic, 1991). Also Tayebati found age-related M1 recep-
tor reduce density in pyramidal neurons of CA1 area of
hippocampus, also M1 receptor density in the radial layer
of CA3 area and in granular layer of the dentate gyrus in
the old rats hippocampus have been observed (Tayebati et
al., 2002).
Some studies have shown that in Alzheimer's disease
the immunoreactivity decreased in M1 receptor (Flynn et
al., 1995; Shiozaki et al., 2001). The other researches showed
that in patients with Alzheimer’s disease, M1 receptor
agonists are proposed to increase cognitive function and
neurogenesis (Fisher, 2008; Ma et al., 2009).
Araujo et al. (2011) showed that injection of
scopolamine (15 mg/kg; SC) to dogs, reduces significantly
the density of muscarinic receptor in older dogs in the frontal,
parietal, and entorhinal segments. In this research similar to
our study the reduction of muscarinic neurons was found.
CONCLUSION
It seems changes in the number of M1 receptors occur
in some phenomenon such as aging and Alzheimer's disease.
Therefore, we concluded that scopolamine as muscarinic
acetylcholine receptor antagonist impairs the avoidance
memory and it can reduce dose-dependently the density of
M1-neurons in hippocampus.
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RESUMEN: El sistema colinérgico en el SNC está implicado en el aprendizaje y la memoria. La escopolamina como receptor
antagonista de acetilcolina muscarínico es utilizada para la creación del deterioro de la memoria. El propósito de este estudio es la
evaluación de la amnesia  basada en escopolamina  sobre la retención de memoria y el efecto de este fenómeno en la cantidad de
neuronas  en receptores M1 en regiones del hipocampo en ratas macho Wistar. Se distribuyeron al azar, 35 ratas macho Wistar (200±20
g) en cinco grupos. El grupo de control (muestras intactas) y 3 grupos experimentales con grupo de tratamiento simulado (solución
salina) analizadas por método de evasión pasiva (caja de transporte) en dosis de 0,2; 0,5 y 1 mg/kg (por vía intraperitoneal) como dosis
única. Al término de una semana se realizó prueba de memoria de las ratas. Por último, los cerebros diseccionados de las ratas sacrifica-
das y los tejidos procesados fueron teñidos con anticuerpos contra los receptores M1 (técnica inmunohistoquímica), seguido por el
recuento de regiones CA1, CA3 y DG del hipocampo. Nuestros resultados mostraron una disminución significativa en las neuronas con
receptores M1 en toda el área del hipocampo. Se encontró que el número menor de neuronas M1, y fue demostrado en 1 mg/kg de dosis
de escopolamina. Llegamos a la conclusión de que la escopolamina como antagonista del receptor de acetilcolina muscarínico puede,
dependiendo de la dosis, reducir la densidad de neuronas M1 en todas las áreas del hipocampo.
PALABRAS CLAVE: Receptor M1; Escopolamina; Evasión de memoria; Hipocampo; Rata.
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